Abstract
Efforts to develop novel, interferon-sparing therapies for treatment of chronic hepatitis C (HCV) infection are contingent on the ability of combination therapies consisting of direct antiviral inhibitors to achieve a sustained virologic response. This work demonstrates a proof of concept that coadministration of the nucleoside analogue MK-0608 with the protease inhibitor MK-7009, both of which produced robust viral load declines as monotherapy, to an HCV-infected chimpanzee can achieve a cure of infection.
MeSH terms
-
Animals
-
Antiviral Agents / administration & dosage*
-
Antiviral Agents / pharmacology
-
Antiviral Agents / therapeutic use
-
Cyclopropanes
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Drug Therapy, Combination
-
Hepacivirus / drug effects*
-
Hepacivirus / enzymology
-
Hepacivirus / physiology
-
Hepatitis C, Chronic / drug therapy*
-
Hepatitis C, Chronic / virology
-
Indoles / administration & dosage*
-
Indoles / pharmacology
-
Indoles / therapeutic use
-
Isoindoles
-
Lactams, Macrocyclic
-
Leucine / analogs & derivatives
-
Pan troglodytes / virology*
-
Proline / analogs & derivatives
-
Protease Inhibitors / administration & dosage
-
Protease Inhibitors / pharmacology
-
Protease Inhibitors / therapeutic use
-
Sulfonamides
-
Treatment Outcome
-
Tubercidin / administration & dosage
-
Tubercidin / analogs & derivatives*
-
Tubercidin / pharmacology
-
Tubercidin / therapeutic use
-
Viral Load / drug effects*
-
Viral Nonstructural Proteins / antagonists & inhibitors
Substances
-
Antiviral Agents
-
Cyclopropanes
-
Indoles
-
Isoindoles
-
Lactams, Macrocyclic
-
NS3 protein, hepatitis C virus
-
Protease Inhibitors
-
Sulfonamides
-
Viral Nonstructural Proteins
-
Proline
-
vaniprevir
-
Leucine
-
Tubercidin
-
7-deaza-2'-C-methyladenosine